Posted by Lindsey Winhoffer on Jan 22nd, 2025
Keros Therapeutics, Inc. (NASDAQ:KROS – Free Report) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Keros Therapeutics in a note issued to investors on Tuesday, January...
More of this article »